Eli Lilly And Company Earnings

Eli Lilly And Company’s revenue jumped 45.17% since last year same period to $12728.5Mn in the Q1 2025. On a quarterly growth basis, Eli Lilly And Company has generated -5.94% fall in its revenue since last 3-months.

Eli Lilly And Company’s net profit jumped 23.02% since last year same period to $2759.3Mn in the Q1 2025. On a quarterly growth basis, Eli Lilly And Company has generated -37.43% fall in its net profits since last 3-months.

Eli Lilly And Company’s net profit margin fell -15.26% since last year same period to 21.68% in the Q1 2025. On a quarterly growth basis, Eli Lilly And Company has generated -33.47% fall in its net profit margins since last 3-months.

Eli Lilly And Company’s price-to-earnings ratio after this Q1 2025 earnings stands at 62.89.

Eli Lilly And Company’s earning per share (EPS) estimates for the current quarter stand at 6.14 - a 10.43% jump from last quarter’s estimates.

Eli Lilly And Company’s earning per share (EPS) estimates for the current year stand at 6.14.

Eli Lilly And Company’s earning per share (EPS) fell -100% since last year same period to 0 in the Q2 2025. This indicates that the Eli Lilly And Company has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Eli Lilly And Company declared 1.5 dividend per share during the earnings announcement for Q2 2025.